2717-95-5

Usage

Uses

Used in Pharmaceutical Applications:
3-[(Dimethylamino)methyl]imidazo[1,2-a]pyridine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs, potentially offering novel therapeutic options.
Used in Material Science Applications:
In the field of material science, 3-[(Dimethylamino)methyl]imidazo[1,2-a]pyridine is used as a building block for the creation of new materials with specific properties. Its incorporation into materials can lead to advancements in areas such as electronics, optics, and nanotechnology, where novel materials with tailored characteristics are constantly sought after.
Used in Research and Development:
3-[(Dimethylamino)methyl]imidazo[1,2-a]pyridine is utilized as a research compound in academic and industrial laboratories. Its complex nature and potential for various applications make it an interesting subject for further study and exploration, with the aim of uncovering its full range of functionalities and characteristics.

Upstream product

• 274-76-0 imidazo[1,2-a]pyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 50-00-0 formaldehyd 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 17744-98-8 2-(imidazo[1,2-a]pyridin-3-yl)acetonitrile 
• 1312891-90-9 (E)-3-(4-{[2-(imidazo[1,2-a]pyridin-3-yl)ethylamino]methyl}phenyl)acrylic acid methyl ester 
• 1312891-52-3 (E)-N-hydroxy-3-(4-{[2-(imidazo[1,2-a]pyridin-3-yl)ethylamino]methyl}phenyl)acrylamide 
• 664367-52-6 2-(imidazo[1,2-a]pyridin-3-yl)ethylamine 
• 6188-43-8 imidazo[1,2-a]pyridine-3-carbaldehyde 

Relevant academic research and scientific papers

Aminomethylation of imidazopyridines using N,N-dimethylformamide as an aminomethylating reagent under Cu(II)-catalysis

N,N-Dimethylformamide has been explored as an aminomethylating reagent in the functionalization of imidazopyridine under Cu(II)-catalysis. A library of aminomethylated imidazopyridines with broad functionalities was synthesized in good yields.

INDOLE AHR INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.